1/31/2013

Navidea Biopharmaceuticals said it has sold 1.5 million shares to J.P. Morgan Chase & Co.'s asset management unit and an additional investor to raise money to support its operations while it waits for an FDA decision on its radiopharmaceutical agent Lymphoseek. Navidea expects a decision in April and is also pursuing European approval for the agent.

Related Summaries